Drug Profile

NTX 250

Alternative Names: NTX-0250; NTX250

Latest Information Update: 09 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nutcracker Therapeutics
Class Antineoplastics; Immunotherapies; RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

07 Nov 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Nutcracker Therapeutics
19 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2023)
19 Apr 2023 Nutcracker Therapeutics plans a phase I trial for Cancer in early 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com